Fox Chase Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Fox Chase Cancer Center sits in the top decile of US sponsors by registered trial count (#164 of 15,742 sponsors by registered trial count).
Fox Chase Cancer Center: 183 sponsored US clinical trials, 29 recruiting.
Fox Chase Cancer Center sponsors 183 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 104 completed. 5 of these trials are in Phase 3-4 (later-stage) and 107 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urothelial Carcinoma, with 6 trials.
Top-decile sponsor footprint
Fox Chase Cancer Center ranks in the top decile of sponsors by registered trial count (#164 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
104 of 137 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
183 total, page 3 of 4
Development of Real-time Image-guided Radiotherapy
NCT03524248
Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors (PROGRESS)
NCT02224482
3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors
NCT01470365
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
NCT01462630
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
NCT01471964
Comparative Effectiveness of CTC & OC
NCT02143115
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
NCT01212822
A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults
NCT02147080
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT01316757
Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
NCT01982591
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
NCT01281514
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT01169532
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
NCT01285102
Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA Men
NCT01937585
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT01280643
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT01059552
Dose Dense MVAC for Muscle Invasive Bladder Cancer
NCT01031420
Cervical Cancer Screening Intervention Among Korean American Women
NCT02594826
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
NCT01089595
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
NCT01637194
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
NCT00761345
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
NCT01183559
Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations
NCT00700778
Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)
NCT00782834
Couple-Focused Intervention for Breast Cancer Patients
NCT00940277
The Effects of MBSR in Improving Immune Response to Human Papillomavirus in Patients With Cervical Dysplasia
NCT00653146
Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
NCT00900016
Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
NCT00553800
Physical Activity or Usual Care in Preventing Weight Gain in Women With Stage I or Stage II Breast Cancer Undergoing Chemotherapy
NCT00509626
Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer
NCT00450424
Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants
NCT00478309
Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer
NCT00394147
Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children
NCT00458588
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
NCT00350025
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
NCT00372840
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
NCT00321100
Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer
NCT00604409
The Skin Savvy Study: A Behavioral Skin Cancer Prevention Intervention
NCT00709306
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
NCT00365508
Traditional Print Communication Methods, Simple Electronic Communication Methods, or Usual Care in Increasing How Often Older Women Undergo Colorectal Cancer Screening
NCT00459030
Tailored Intervention for Melanoma Patient's Families
NCT00816374
Educational Intervention With or Without Telephone Counseling in Increasing Colorectal Cancer Screening Compliance in Brothers and Sisters of Patients With Colorectal Cancer
NCT00352638
Facilitating Follow-Up Adherence for Abnormal Pap Smears
NCT01561326
Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting
NCT01440855
Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer
NCT00315185
Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
NCT00084513
Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer
NCT00084552
Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer
NCT00084591
Genetic and Environmental Risk Assessment for Colorectal Cancer in Healthy Participants
NCT00087360
Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
NCT00101335
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 45 |
| Phase 2 | 62 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Fox Chase Cancer Center pipeline
29 recruiting of 183 indexed (16% open); 104 completed (57%).
Phase mix: 5 late (III/IV) vs 107 early (I/II) (early-phase heavy).
Top condition: Urothelial Carcinoma (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fox Chase Cancer Center: open-pipeline peers nationwide
Peers matched on 183 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
Fox Chase Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 183 trials (± recruiting share)
- Children's Mercy Hospital Kansas City · 184 trials · 11% recruiting
- ViiV Healthcare · 182 trials · 4% recruiting
- Boston University · 185 trials · 12% recruiting
- National Human Genome Research Institute (NHGRI) · 185 trials · 16% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- University of California, San Francisco · 16% recruiting · 1,713 trials
- Youngstown State University · 16% recruiting · 19 trials
- University of Southern California · 16% recruiting · 617 trials
Related
What to do with this Fox Chase Cancer Center page
183 registered trials is a research-attention snapshot, not an endorsement of Fox Chase Cancer Center or any single study.
- 29 of Fox Chase Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Urothelial Carcinoma is the condition Fox Chase Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urothelial Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Fox Chase Cancer Center pipeline card: 183 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.